10x Genomics Ordered to Pay $23.9 Million for Infringing Bio-Rad’s Patents
Case: The Federal District Court jury found that 10x willfully infringed three genetic analysis technology patents that Bio-Rad licensed from the University of Chicago on an exclusive basis. Specifically, the jury concluded that all single-cell and linked-read genomics products sold by 10x, including GemCode Long Read, Chromium Genome/Exome and Chromium Single Cell 3 willfully infringed the patented technology. Significance: The court case is just one front in the IP war between the firms. 10x has filed a complaint with the International Trade Commission accusing Bio-Rad of illegally importing microfluidic systems violating its own patents into the US for sale. 10x also issued a statement expressing its strong disagreement with the court verdict and its intention to appeal.
Case: The Federal District Court jury found that 10x willfully infringed three genetic analysis technology patents that Bio-Rad licensed from the University of Chicago on an exclusive basis. Specifically, the jury concluded that all single-cell and linked-read genomics products sold by 10x, including GemCode Long Read, Chromium Genome/Exome and Chromium Single Cell 3 willfully infringed the patented technology.
Significance: The court case is just one front in the IP war between the firms. 10x has filed a complaint with the International Trade Commission accusing Bio-Rad of illegally importing microfluidic systems violating its own patents into the US for sale. 10x also issued a statement expressing its strong disagreement with the court verdict and its intention to appeal.
Subscribe to view Essential
Start a Free Trial for immediate access to this article